Verici Dx has added further clinical support for its pre-transplant kidney rejection risk test, reinforcing the company’s positioning in a specialist area of diagnostics where better patient stratification could carry meaningful clinical and commercial relevance.
The company’s Pre-Transplant Risk Assessment test, known as PTRA, is designed to evaluate a patient’s immune profile before kidney transplantation and identify whether they are at higher or lower risk of early acute rejection. A risk signal before transplant could help clinicians make more informed decisions around immunosuppressive treatment, rather than relying only on conventional donor and recipient characteristics.
The validation work focused on a blood-based next-generation sequencing assay that measures RNA expression through a 29-gene signature. In the study, PTRA was used to stratify deceased donor kidney transplant recipients into high-risk and low-risk groups for early acute rejection. The results indicated that the test was able to differentiate between those groups, with early rejection events occurring more frequently among patients classified as high risk.
Acute rejection remains one of the key clinical risks following kidney transplantation. Current approaches to assessing risk can be limited, and standardised immunosuppressive regimens may not fully reflect the individual biology of each patient. A test that helps identify patients who may need closer monitoring or adjusted treatment could support a more personalised approach, which is increasingly important across transplant medicine.
For Verici Dx, the publication and validation of PTRA provide another step in building the evidence base around its transplant diagnostics platform. The company is also continuing to collect longer-term patient outcome data while progressing development of a next-generation sequencing based risk assessment test for kidney fibrosis.
Verici Dx Plc (LON:VRCI) is developing a complementary suite of proprietary, leading-edge tests forming a kidney transplant diagnostics platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes.
